T-Cell Engager Therapies: Addressing Challenges & Advancing Next- Generation Approaches
- Tackling key hurdles in TCE development including target discovery, safety concerns, T-cell exhaustion, and limited response rates to improve clinical outcomes despite TCEs being a clinical validated concept
- Overviewing next-generation approaches, such as co-stimulation, TCR mimics, masked TcEs, and engagement of alternative cell types – aim to unlock novel targets, enhance tumour selectivity, and enable differentiated mechanisms of action (MoA)
- Showcasing Boehringer Ingelheim’s progress in advancing TCE technologies toward safer, more effective translation